The blood-brain barrier protects the brain from poisons but also prevents drugs from reaching brain tumors; innovative new treatments are needed.
This laboratory study shows that a nanotechnology drug called SapC-DOPS crosses that barrier and targets brain-tumor cells and retards growth of tumor blood vessels. The findings also show how the agent targets tumor cells and recommend its further development as a novel treatment for glioblastoma.
An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels. The findings support further development of the drug as a novel treatment for brain tumors.
Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months. A major obstacle to improving treatment for the 3,470 cases of the disease expected in the United States this year is the blood-brain barrier, the name given to the tight fit of cells that make up the blood vessels in the brain. That barrier protects the brain from toxins in the blood but also keeps drugs in the bloodstream from reaching brain tumors.
“Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells,” says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC – James. “Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors.”
The findings were published in a recent issue of the journal Molecular Therapy.
SapC-DOPS (saposin-C dioleoylphosphatidylserine), is a nanovesicle drug that has shown activity in glioblastoma, pancreatic cancer and other solid tumors in preclinical studies. The nanovesicles fuse with tumor cells, causing them to self-destruct by apoptosis.
Key findings of the study, which used two brain-tumor models, include:
The Latest Bing News on:
- UPI: Promising pancreatic cancer treatmenton June 15, 2020 at 8:21 am
The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously ...
The Latest Google Headlines on:
The Latest Bing News on:
- Strategies for delivering therapeutics across the blood–brain barrieron March 1, 2021 at 8:39 am
The blood–brain barrier is a perennial challenge for the delivery of therapeutics to the central nervous system. In their Review, Terstappen and colleagues discuss non-invasive approaches to brain ...
- Researchers watch anti-cancer drug release from DNA nanostructures in real timeon March 1, 2021 at 7:39 am
To tackle this emerging question, a team of researchers from Aalto University (Finland), the University of Jyväskylä (Finland), Ludwig-Maximilian-Universität München (Germany) and Universität ...
- Demand For Nanoparticles In Medicine Drives Growth Of The Nanosilica Industryon February 28, 2021 at 6:58 pm
Increased demand for nanoparticles in the medical industry contributed to the growth of the nano-silica market. Nanoparticles are presently being engaged as a tool to explore the ...
- Light-twisting 'chiral' nanotechnology could accelerate drug screeningon February 26, 2021 at 12:19 pm
A new approach makes liquid-crystal-like beacons out of harmful amyloid proteins present in diseases such as Type II diabetes.
- Influence of bound dodecanoic acid on the reconstitution of albumin nanoparticles from a lyophilized state | Scientific Reportson February 26, 2021 at 10:03 am
Here, we examine factors that influence the properties of cross-linked albumin nanoparticles, fabricated with an ethanol desolvation method, when reconstituted from a lyophilized state. We demonstrate ...
- VIDEO: On the Line: Watching Nanoparticles Get in Shapeon February 26, 2021 at 7:36 am
Real-time video of 70 nm nanoparticles (red) and 500 nanometer nanoparticles (green) captured via laser scanning confocal microscopy at the Molecular Foundry. (Credit: Paul Ashby and Tom ...
- On the line: Watching nanoparticles get in shapeon February 25, 2021 at 12:27 am
Now, a research team led by Berkeley Lab has captured real-time high-resolution videos of liquid structures taking shape as nanoparticle surfactants (NPSs) - soap-like particles just billionths of a ...
- Nanostructured Drug Market Size, Share, Growth, Sales and Drivers Analysis Research Report 2027on February 23, 2021 at 6:12 pm
Market Research Engine has published a new report titled as "Nanostructured Drug Market Size by Product (Liposomes, ...
- Okayama University research: Nanotechnology for making cancer drugs more accessible to the brainon February 22, 2021 at 8:11 pm
In a study reported in the Journal of Controlled Release, researchers from Okayama University describe the use of nanocarriers in ...
- Gold nanoparticles investigated as part of in vitro tool for SARS-CoV-2 drug screeningon February 20, 2021 at 4:00 pm
These nanoparticles functionalized with the S protein have different ... that their S protein model system can be potentially used as an in vitro tool for drug screening. Researchers Kazushige ...